AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01145014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 600 mg oral drinking solution
Study NCT01145014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 10,0 mg immediate release tablet
Study NCT01145014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 660848
Description: 50,0 mg immediate release tablet
Study NCT01145014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo (oral drinking solution and IR tablets)
Study NCT03459599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic antibiotics
Description: Amox-clav given to eligible women as per existing protocol, which is 625mg three times a day, for a week
Study NCT03459599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No prophylaxis (Amox-clav withheld)
Description: Withholding Amox-clav, which is the current local practice for women with ragged placental membranes. This was replaced with appropriate counselling on signs and symptoms of endometritis, when and where women should present if the symptoms above occur. A follow up phone call was performed at 2 weeks and 6 weeks postpartum to ascertain well-being of patients
Study NCT02509104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC capsule of dutasteride and tamsulosin
Description: Each FDC capsule contains a mixture of dutasteride formulation (equivalent to 0.5 mg dutasteride) and tamsulosin (equivalent to 0.2 mg tamsulosin) and its physical appearance is hard shell capsule.
Study NCT02509104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet
Description: Coadministration of dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet. Each soft gelatine capsule consist of 0.5 mg of dutasteride and physical appearance is Oblong, size 6, dull yellow capsule. Each oral disintegrating tablet consist of 0.2 mg of tamsulosin and its physical appearance is white, round standard convex.
Study NCT01840891 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactose H2 breath test (LH2BT)
Description: Prevalence of lactose intolerance stated with a positive LH2BT and/or a positive LTT in RTRs with chronic norovirus infection.
Study NCT01840891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lactose H2 breath test (LH2BT)
Description: Prevalence of lactose intolerance stated with a positive LH2BT and/or a positive LTT in RTRs with chronic norovirus infection.
Study NCT01069120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex
Description: 2, 25 mg capsules once per day
Study NCT01069120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex
Description: 1, 25 mg capsule once per day
Study NCT00388505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin Inhalation Powder
Description: Tobramycin Inhalation Powder (TIP) capsules for inhalation.
Study NCT00388505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin Solution for Inhalation
Description: Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer
Study NCT02529267 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Study NCT04038840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]UCB-J radiotracer
Description: I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein
Study NCT04038840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET-MR
Description: Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
Study NCT04195373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TMV-018 + 5-FC
Description: TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment.
Study NCT04195373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TMV-018 + anti-PD-1
Description: TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~Anti-PD-1 inhibitor dose according to its SMPC.
Study NCT04195373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TMV-018 + 5-FC + anti-PD-1
Description: TMV-018: liquid frozen, life attenuated, oncolytic measles virus encoding the prodrug converting enzyme super cytosine deaminase; 1E+06 TCID50 to 1E+08 TCID50 per dose.~5-FC: 150 mg/kg/day for 2 days during each treatment cycle.~Anti-PD-1 Inhibitor: dose according to its SMPC.
Study NCT01043419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xenon
Description: Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes
Study NCT01391546 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX
Description: 1 dose 0.65 mL
Study NCT01391546 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ZOSTAVAX
Description: 1 dose 0.65 mL
Study NCT04012957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desidustat Oral Tablet
Description: Desidustat tablet
Study NCT04012957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Darbepoetin injection
Study NCT01213472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)
Description: Up to 24 intramuscular administrations
Study NCT02247765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial line
Description: Arterial line is inserted to draw a CO-Oximeter value as it is the gold standard and as advised in ISO 80601
Study NCT02247765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motion
Description: The subject is asked to move their hand by either rubbing or tapping their fingers at a specified frequency and amplitude during portions of the hypoxic procedure.
Study NCT02827123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath MAC videolaryngoscopy
Description: Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
Study NCT02827123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Macintosh Laryngoscopy
Description: Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
Study NCT01905124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CF101
Description: CF101 1 mg tablets orally every 12 hours for 24 weeks
Study NCT01905124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets orally every 12 hours for 24 weeks
Study NCT02709590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac potassium + lidocaine
Description: patients will have of oral diclofenac potassium 60 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before HSG
Study NCT02709590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will have of oral placebo tablet 60 minutes before the procedure plus placebo cream placed into their cervix immediately before HSG
Study NCT00564005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint-induced therapy (CIT)
Description: restraint of the unaffected arm and practice of the affected arm
Study NCT00564005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral arm training (BAT)
Description: bilateral symmetric, repetitive arm training
Study NCT00564005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined therapy (CT)
Description: combined different treatment approaches
Study NCT00564005 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Conventional treatment program
Study NCT02088814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 'EPICAP'
Description: standardized, secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
Study NCT04644380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVOcell
Description: Female participants undergoing in vitro fertilization (IVF) and or/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproductive will be asked to participate
Study NCT05804760 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of implant parameters
Description: 1. Examination of the inclusion criteria~2. Medical history/patient-specific data (smoking, tumour diseases, radiation, gender, number of implants, history of periodontitis).~3. Recording of implant-specific parameters (measurement depth at six sites per implant(probing depth/PD), bleeding and or pus on probing (BOP) at six measurement sites per implant, condition of the peri-implant mucosa using the modified plaque index(mPI) and the modified ginigiva index (mGI), measurement of the width of the keratinised mucosa(KM), type of denture, approximal plaque index (API), radiographically detectable bone resorption.
Study NCT02253368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sleep
Study NCT01291199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vardenafil
Description: 10 mg p.o. bid for 6 weeks
Study NCT01291199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vardenafil
Description: 10 mg p.o. bid for 6 weeks
Study NCT01291199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. 6 weeks bid
Study NCT01291199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo p.o. 6 weeks bid
Study NCT01186939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m\^2/day.
Study NCT01091597 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: usual PV ablation
Description: usual PV ablation, per above
Study NCT01091597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Box isolation of pulmonary veins
Description: as above
Study NCT04357704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S0N0
Description: (no ITD)
Study NCT04357704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S0N0
Description: (no ITD)
Study NCT04357704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S0N500
Description: (ITD +500µs on noise)
Study NCT04357704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S0N500
Description: (ITD +500µs on noise)
Study NCT04357704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-500N500
Description: (ITD -500µs on signal and +500 µs on noise)
Study NCT04357704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S-500N500
Description: (ITD -500µs on signal and +500 µs on noise)
Study NCT04357704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S0N1000
Description: (ITD + 1000 µs on noise)
Study NCT04357704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S0N1000
Description: (ITD + 1000 µs on noise)
Study NCT04357704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S0Nuncorr
Description: (no ITD cue, with uncorrelated stimulation frame)
Study NCT04357704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S0Nuncorr
Description: (no ITD cue, with uncorrelated stimulation frame)
Study NCT01025024 — intervention group
Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample
Study NCT00636688 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle - detailed advice
Description: Detailed advice about how to achieve a loss of 10% or more in their total body weight by reducing caloric intake and increasing their level of physical activity
Study NCT00636688 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - general information
Description: General information about healthy food choices and exercise
Study NCT03163979 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET/CT and Comet assay guide RapidArc
Description: 1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
Study NCT03163979 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET/CT and Comet assay guide IMRT
Description: Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
Study NCT03163979 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RapidArc
Description: RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used.
Study NCT03163979 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: 7f-IMRT
Description: seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
Study NCT03352102 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Neuromuscular electrical stimulation therapy was performed
Study NCT03352102 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation
Description: Neuromuscular electrical stimulation therapy was performed
Study NCT00072839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX-0600
Description: teduglutide
Study NCT00072839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo solution injected subcutaneously
Study NCT00072839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide 0.05
Description: 0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
Study NCT00072839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide 0.2 mg
Description: 0.2 mg/kg/d subcutaneously injected into thigh or abdomen
Study NCT00072839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide 0.05 dose
Description: 0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
Study NCT00072839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide 0.1 mg dose
Description: 0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
Study NCT02213432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Different timing of influenza vaccination
Description: The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.
Study NCT02213432 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Different timing of influenza vaccination
Description: The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.
Study NCT02136745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response Mind-Body Intervention
Description: The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. Three consecutive, mixed-disorder groups, ranging in size from 10 to 18 participants each. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
Study NCT00395551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5mg intravitreal injection
Study NCT04248582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: LNSC will be performed with low-pressure liquid nitrogen (\<5 psi) at 25 watts using a cryotherapy catheter passed through the working channel of the endoscope.We will plan to administer LNSC as follows: up to three cycles of 20 to 40 seconds each directed at the bulkiest aspect of the tumor. During each cycle, a surface area of approximately 2 to 3 cm2 is targeted. Up to three sites are treated during each session. Tissue thawing is verified between cycles by waiting at least 60 seconds before re-treatment, and by observing a return to baseline color of the tissue and complete disappearance of ice crystals after reperfusion. After the procedure is completed, patients will be monitored in the recovery unit for at least 30 minutes. Patients will be discharged after monitoring if they meet the endoscopy unit's standard discharge criteria.
Study NCT00436618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
Study NCT04170712 — intervention group
Intervention type: OTHER
Intervention: Tampons
Description: Collection of tampons, blood, cervical swabs, tissue and ascites
Study NCT04292028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The Pilates group participated in an 8-week clinical Pilates training program
Study NCT04292028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercises
Description: Control group were given a home-based exercise program.
Study NCT02595021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total or Subtotal Colectomy
Description: Resect all or most parts of the colon: with total or subtotal colectomy as a part of optimal cytoreductive surgery(residual disease \<=0.5cm)
Study NCT02595021 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Other Bowel Resection
Description: Resect part of the colon or small intestine: with other types of bowel resection as a part of optimal cytoreductive surgery(residual disease \<=0.5cm)
Study NCT01755845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01755845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Study NCT01755845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT01755845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Study NCT01755845 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Study NCT01755845 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Study NCT00733304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD
Study NCT02596620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexium
Description: Esomeprazole (Nexium)(40 mg) 1 tablet twice daily for 10 days in both arms
Study NCT02596620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: Esomeprazole (Nexium)(40 mg) 1 tablet twice daily for 10 days in both arms
Study NCT02596620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amolin
Description: Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for the first 5 days in the Sequential arm; Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 10 days for triple therapy arm
Study NCT02596620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amolin
Description: Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for the first 5 days in the Sequential arm; Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 10 days for triple therapy arm
Study NCT02596620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cravit
Description: Levofloxacin(Cravit)(500 mg) 1 tablet once dialy for the last 5 days in the sequential arm and 1 tablets once daily for 10 days in the triple therapy arm
Study NCT02596620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cravit
Description: Levofloxacin(Cravit)(500 mg) 1 tablet once dialy for the last 5 days in the sequential arm and 1 tablets once daily for 10 days in the triple therapy arm
Study NCT02596620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flagyl
Description: Metronidazole (Flagyl)(250 mg) 2 # tid for the last 5 days in the sequential arm